The Radiopharmaceuticals Market is expected to be valued US$ 6.2 billion in 2022, according to Future Market Insights (FMI). During the projected period of 2022-2032, radiopharmaceutical consumption is expected to grow at a 4.3% CAGR to reach US$ 9.5 billion.
North America will account for more than 47% of the global market due to increased cancer incidence and the expansion of the healthcare industry in the United States and Canada.
Siemens AG, General Electric Co. (GE Healthcare), Curium, Lantheus Holdings, Inc., and Eckert & Ziegler are among the major players, according to FMI. The top businesses account for more than 90% of revenue in the global radiopharmaceuticals market.
Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1992
Prominent Players:
Siemens AG
Positron Corporation
Novartis (Advanced Accelerator Applications)
Curium
GE Healthcare
Lantheus Holdings Inc.
Sotera Health LLC
Bayer AG
Eckert & Ziegler
Key Takeaways from FMI’s Radiopharmaceuticals Market Study
In terms of application, oncology will contribute over 50% of global market share owing to the rising prevalence of cancer across the globe.
Cyclotrons are expected to be the primary source of radiopharmaceuticals, accounting for maximum market share
Based on radioisotope type, technetium-99 will remain highly preferred radioisotope in the global radiopharmaceutical market
The U.S. will retain its global dominance backed by the high cancer and cardiovascular cases rising in the country
India will emerge as lucrative market owing to the favorable government initiatives promoting the radiopharmaceuticals market
Germany and the U.K. are spearheading the growth of Europe market, which is projected to grow at over 4.9% CAGR
Enquiry/Query @ https://www.futuremarketinsights.com/ask-question/rep-gb-1992
“Increasing research and development initiatives aimed at the production of advanced radioisotopes and novel technologies will improve growth prospects for the leading players in the radiopharmaceuticals market,” says the FMI analyst.
Competitive Landscape
Leading radiopharmaceuticals market players are focusing on expanding their customer base through strategic mergers and acquisition. Increasing research and development activities to develop advanced radioisotopes for the cancer treatment is another core strategy adopted by leading players.
Top 5 players including Siemens AG, GE Healthcare, Curium, Lantheus Holdings Inc., and Eckert & Ziegler are dominating the global radiopharmaceuticals market, contributing over 90% of revenue share.
In March 2021, Novartis announced the commercialization and obtained the rights to develop the therapeutic applications of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc.
Along with it the company announced the production and commercialization of new nuclear medicine, 18F sodium fluoride radiopharmaceutical in France.
In November 2020, Blue Earth Diagnostics, a leading molecular imaging diagnostic company, unveiled that their manufacturing company, Nucleis has manufactured and shipped their first doses of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen (PSMA)-targeted radiohybrid PET imaging agent, for patients with prostate cancer.
Another industry giant, Jubilant Pharma Limited Company, in 2019, announced the integration of its radiopharmaceutical drug development and manufacturing business with its radio-pharmacy business into a global radiopharmaceutical brand, Jubilant Radiopharma.
Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-1992
Radiopharmaceuticals Market by Category
By Radioisotope Type:
Technetium-99
Fluorine-18
Iodine-131
Leutetium-177
Yttrium-90
Gallium-68
Gallium-67
Rubidium-82
Iodine-123
Iodine-125
Indium-111
Others
By Application:
Oncology
Cardiology
Gastroenterology
Neuroendocrinology
Neurology
Nephrology
Others
By Source:
Cyclotrons
Nuclear Reactors
By End-User:
Hospitals
Diagnostic Imaging Centers
Ambulatory Surgical Centers
Cancer Research Institute
Use promo code ->> FMITODAY to get flat 30% discount
Explore FMI’s Extensive ongoing Coverage on Healthcare Domain:
- https://faceblox.mn.co/posts/30396229
- https://primal-dread.mn.co/posts/bovine-lactoferrin-market-to-expand-at-a-158-value-cagr-by-2033-says-fmi-analyst
- https://www.patreon.com/posts/bovine-market-to-76198888?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=postshare_creator&utm_content=join_link
- https://drujrake.mn.co/posts/30396325
- https://cigarbook.mn.co/posts/30396353
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs